28-02-2020
PictureDesignSwiss / Shutterstock.com
The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Biogen, biotech, injunction, US Court of Appeals for the Federal Circuit, Banner Life Sciences, Sangamo, collaboration, gene therapies
Pharma company fails to block €140m licence payment
23-06-2021
Biogen sues Teva over MS generic
18-03-2021
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
Fed Circuit rejects Biogen’s plea in MS drug dispute
23-04-2020
Biogen takes Creative Biolabs to court over antibody
19-03-2020
Biogen fights off Mylan’s Tecfidera patent challenge
06-02-2020
